Biocon: board okays share swap for ~2% of BBL, Q4 results, Re. 0.50 dividend
Biocon · Pharmaceuticals & Biotechnology
Key highlights
- Biocon to issue up to 87,92,317 equity shares at Rs. 376.16 each (up to Rs. 330.73 Crores) to 127 BBL shareholders for up to 1,15,36,956 BBL shares; shareholder approval needed.
- Board approved conversion of 1,125 OCDs into 4,11,11,689 BBL equity shares and 1,06,86,044 CCDs into 1,06,86,044 BBL equity shares; Biocon to hold ~99.99% of BBL.
- S. R. Batliboi & Associates LLP recommended as statutory auditors for 5 years from the 48th AGM (August 06, 2026), replacing B S R & Co. LLP; final dividend Re. 0.50/- per share recommended.
Why it's rated notable: the year-on-year change is 141% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Issue of Securities
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Biocon
- Order winNotableBiocon secures 10-year Pertuzumab supply contract in Brazil under PDP program
- Acquisition / mergerMajor developmentBiocon Limited board approves Q4 results, dividend, auditor change and BBL share swap
- Dividend / buyback / bonusMajor developmentBiocon board approves share swap to acquire remaining BBL stake via preferential issue
- Dividend / buyback / bonusMajor development· Adverse for the businessBiocon reports Q4FY26, FY26 consolidated results; profit before exceptionals down YoY
- Acquisition / mergerNotableBiocon Limited announces acquisition of Biocon Biologics shares via preferential issue
Other fundraise / allotment filings this fortnight
- IIFL Finance Limited announces preferential issue of shares and amendments on Nov 10, 2026
- IIFL Finance to raise ₹6,414 crore in primary equity infusion led by Blackstone
- Bajaj Finserv subscribes to 5,74,25,740 Bajaj Finance warrants at ₹1,010 each
- Supreme Engineering allots 14,50,00,000 warrants at ₹2.60 on preferential basis
- Bajaj Finance Limited allots 5.74 crore warrants to Bajaj Finserv on 10 Nov 2026
- Bajaj Finance approves preferential issue of 5.74 crore warrants to Bajaj Finserv
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.